Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Case Study · August 20, 2015

Complete Response Rate in Cutaneous Metastatic Melanoma Treated With Intralesional IL-2, Imiquimod, and Topical Retinoid Combination Therapy

Journal of the American Academy of Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
100% Complete Response Rate in Patients With Cutaneous Metastatic Melanoma Treated With Intralesional Interleukin (IL)-2, Imiquimod, and Topical Retinoid Combination Therapy: Results of a Case Series
J Am Acad Dermatol 2015 Aug 07;[EPub Ahead of Print], VY Shi, K Tran, F Patel, J Leventhal, T Konia, MA Fung, R Wilken, MS Garcia, SD Fitzmaurice, J Joo, AM Monjazeb, BA Burrall, B King, S Martinez, SD Christensen, E Maverakis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading